A randomized trial of ribavirin and interferon-α vs. interferon-α alone in patients chronic hepatitis C who were non-responders to a previous treatment

Journal of Hepatology

Volumn 31, Issue 1, 1999, Pages 1-7

  Pol, Stanislas ^a   Couzigou, Patrice ^a   Bourlière, Marc ^a   Abergel, Armand ^a   Combis, Jean Marc ^a   Larrey, Dominique ^a   Tran, Albert ^a   Moussalli, Joseph ^a   Poupon, Raoul ^a   Berthelot, Pierre ^a   Bréchot, Christian ^a  

^a NONE

Author keywords

Chronic hepatitis; Hepatitis C virus; Interferon ; Non response to interferon

Indexed keywords

ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA;

ANEMIA; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOSTIMULATION; LEUKOPENIA; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; STOMACH CARCINOMA; SUICIDAL BEHAVIOR; TREATMENT OUTCOME; VIRUS DETECTION;

EID: 0032992694     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(99)80157-3     Document Type: Article

References (28)

1. Davis GL, Balart LA, Schiff ER, Lindsay K, Bodenheimer HC Jr, Perrillo RP, the Hepatitis Interventional Therapy Group . Treatment of chronic hepatitis C with recombinant interferon alpha. A multicenter randomized controlled trial. N Engl J Med. 321:1989;1501-1506.
2. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alpha therapy for chronic hepatitis C: a randomized, double-blind, placebo-controlled trial. N Engl J Med. 321:1989;1506-1510.
3. Tiné F, Magrin S, Craxi A, Pagliaro L. Interferon in nonA-nonB hepatitis: a meta-analysis of randomised clinical trials. J Hepatol. 13:1991;192-199.
4. Poynard T, Leroy V, Cohard M, Thevenot T, Mathurin P, Opolon P, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 24:1996;778-789.
5. Chemello L, Cavalletto L, Casarin C, Bonetti P, Bernardinello E, Pontisso P, et al. the TriVeneto Viral Hepatitis Group . Persistent hepatitis C viremia predicts late relapse after sustained response to interferon-α in chronic hepatitis C. Ann Intern Med. 124:1996;1058-1060.
6. Lai M-Y, Kao J-H, Yang P-M, Wang J-T, Chen P-J, Chan K-W, et al. Long-term efficacy of ribavirin plus interferon alfa in the treatment of chronic hepatitis C. Gastroenterology. 111:1996;1307-1312.
7. Chemello L, Cavaletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol. 23:1995;8-12.
8. Reichard O, Norkrans G, Frydén A, Braconier J-H, Sonnerborg A, Weiland O, for the Swedish Study group . A randomized doubleblind, placebo-controlled trial of interferon-α2b with and without ribavirin for chronic hepatitis C. Lancet. 351:1998;83-87.
9. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 352:1998;1426-1432.
10. Brillanti S, Garson J, Foli M, Whitby K, Deaville R, Masci C, et al. A pilot study of combination with ribavirin plus interferon alfa for interferon alfa-resistant chronic hepatitis C. Gastroenterology. 107:1994;812-817.
11. Schvarcz R, Yun ZB, Sonnerborg A, Weiland O. Combined treatment with interferon alpha-2b and ribavirin for chronic hepatitis C in patients with a previous non-response or non-sustained response to interferon alone. J Med virol. 46:1995;43-47.
12. Bellobuono A, Mondazzi L, Tempini S, Silini E, Vicari F, Ideo G. Ribavirin and interferon-alpha combination therapy vs. interferon-alpha alone in the retreatment of chronic hepatitis C: a randomized clinical trial. J Viral Hepat. 4:1997;185-191.
13. Davis GL, Esteban-Mur R, Rustgi V, Hoefs J, Gordon S, Trépo C, et al. the International Hepatitis Interventional Therapy Group . Interferon alfa-2b alone or in combination with ribaririn for the treatment of relapse of chronic hepatitis C. N Engl J Med. 339:1998;1493-1499.
14. Schalm SW, Hansen BE, Chemello L, Bellobuono A, Brouwer JT, Weiland O, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol. 26:1997;961-966.
15. Di Bisceglie AM, Conjeevaram HS, Fried MW, Sallie R, Park Y, Yurdaydin C, et al. Ribavirin as therapy for chronic hepatitis C. A randomized, doubleblind, placebo-controlled trial. Ann Intern Med. 123:1995;897-903.
16. Reichard O, Andersson J, Schvarcz R, Weiland O. Ribavirin treatment for chronic hepatitis C. Lancet. 337:1991;1058-1061.
17. Reichard O, Yun ZB, Sonnerborg A, Weiland O. Hepatitis C viral RNA titers in serum prior to, during, and after oral treatment with ribavirin for chronic hepatitis C. J Med Virol. 41:1993;99-102.
18. Ning Q, Brown D, Parodo J, Cattral M, Gorczynski R, Cole E, et al. Ribavirin inhibits viral induced macrophage production of tumor necrosis factor, interleukin 1, the procoagulant fg12 prothrombinase and preserves TH1 cytokine production, but inhibits TH2 cytokine response. J Immunol. 24:(160):1998;3487-3493.
19. Martin J, Navas S, Quiroga JA, Pardo M, Carreno V. Effect of ribavirin on peripheral blood mononuclear cells from chronic hepatitis C patients. Cytokine. 375:1998;635-644.
20. Scotto G, Ferrara S, Mangano A, Conte PE, Tantimonaco G. Pilot study of a short course of ribavirin and alpha interferon in the treatment of chronic active hepatitis C not responding to alpha-interferon alone. Ital J Gastroenterol. 28:1996;505-511.
21. Camps J, Garcia N, Riezu-Boj JI, Civeira MP, Prieto J. Ribavirin treatment of chronic hepatitis C unresponsive to alfa interferon. J Hepatol. 19:1993;408-412.
22. Thiers V, Jaffredo F, Tuveri R, Chodan N, Bréchot C. Development of a simple restriction fragment length polymorphism (RFLP) based assay for HCV genotyping and comparative analysis with genotyping and serotyping tests. J Virol Methods. 65:1997;9-17.
23. Knodell RG, Ishak KG, Black WG, Chen TS, Craig R, Kaplowitz N, et al. Formulation and application of numerical scoring systems for assessing histological activity in asymptomatic chronic active hepatitis. Hepatology. 5:1981;431-435.
24. NIH Consensus Development Conference. Management of hepatitis C. Hepatology. 26:1997;1S-156S.
25. Pagliaro L, Craxi A, Cammaá C, Tiné F, Di Marco V, Lo Iacono, et al. Interferon-α for chronic hepatitis C: an analysis of pretreatment clinical predictors of response. Hepatology. 19:1994;820-828.
26. Nousbaum JB, Pol S, Nalpas B, Landais P, Berthelot P, Brechot C, a collaborative Study Group . Hepatitis C virus type 1b (II) infection in France and Italy. Ann Intern Med. 122:1995;161-168.
27. Tsubota A, Chayama K, Ikeda K, Yasuji A, Koida I, Saitoh S, et al. Factors predictive of response to interferon-α therapy in hepatitis C virus infection. Hepatology. 19:1994;1088-1094.
28. Pol S, Nalpas B, Vassault A, Bousquet-Lemercier B, Franco D, Lacour B, et al. Hepatic activity and mRNA expression of aspartate aminotransferase isoenzymes in alcoholic and non-alcoholic liver disease. Hepatology. 14:1991;620-625.